Mizuho analyst Anthony Petrone has revised the price target for ResMed (RMD, Financial), lowering it from $280 to $265 while maintaining an Outperform rating. This adjustment is part of a broader first-quarter preview for the medical devices and diagnostics sector.
The analysis highlights several critical factors influencing the decision, including ongoing tariff concerns, potential exposure to market dynamics in China, and the evolving outlook for medical procedures. These elements contributed to a preemptive revision of the financial estimates for ResMed.
Overall, despite the target reduction, the Outperform rating signifies continued confidence in ResMed’s long-term growth potential, with the expectation that the company will navigate these challenges effectively in the coming quarter.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for ResMed Inc (RMD, Financial) is $265.10 with a high estimate of $295.00 and a low estimate of $195.00. The average target implies an upside of 23.90% from the current price of $213.97. More detailed estimate data can be found on the ResMed Inc (RMD) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, ResMed Inc's (RMD, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ResMed Inc (RMD, Financial) in one year is $287.82, suggesting a upside of 34.51% from the current price of $213.97. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ResMed Inc (RMD) Summary page.
